Key information made simple
This study is looking at care and outcomes for people with depression. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
RecruitingNCT06963021
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study is recruiting. It focuses on depression and currently lists participation information in Belgium, Canada, Finland, Hungary, Latvia, the United Kingdom, and the United States.
DepressionOtherOver 18 Years
Your next step
The official record suggests in-person participation through a clinic, with sites including Neurocrine Clinical Site in Los Angeles, Neurocrine Clinical Site in Aurora, and Neurocrine Clinical Site in Cromwell. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and having a stable enough treatment background for the study, while common reasons not to take part include safety concerns that need urgent care first and other treatments that could interfere with the study. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Key study information
- Condition
- Major Depressive Disorder
- Study status
- Recruiting
- Sponsor / lead affiliation
- Neurocrine Biosciences
- Location / country
- Belgium, Canada, Finland, Hungary, Latvia, United Kingdom, United States
- Registry
- ClinicalTrials.gov
Why this study may matter
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Registry reference
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordAsk HopeStage to review this study with me
This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Study reference: NCT06963021. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Belgium.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Things to check before joining
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Main activity
- medication or study treatment
- Intervention
- Not available
- Time commitment
- long follow-up or multiple visits
- Study phase
- Not available
- Enrollment
- Not available
- Recruitment status
- Recruiting
- Source
- Official registry link
Questions about this study
What is NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.
Who is behind this study, and what type of sponsor is it?
This study is sponsored by Neurocrine Biosciences, a biotech company. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company. The sponsor is based in the United States. Sponsor website: https://www.neurocrine.com. You can verify the sponsor and study responsibility in the official registry record.
What does participation involve, what phase is it, and what should I ask about safety?
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Where can I verify the study details?
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.